Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

This FDA Adverse Event Reporting System-based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis-generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug-related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision-making with male patients.